home / stock / syggf / syggf news


SYGGF News and Press, Synairgen PLC Ord

Stock Information

Company Name: Synairgen PLC Ord
Stock Symbol: SYGGF
Market: OTC
Website: synairgen.com

Menu

SYGGF SYGGF Quote SYGGF Short SYGGF News SYGGF Articles SYGGF Message Board
Get SYGGF Alerts

News, Short Squeeze, Breakout and More Instantly...

SYGGF - Synairgen looking beyond COVID in fight against respiratory illness

(NewsDirect) Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden speaks to Thomas Warner from Proactive London about the company's ongoing efforts to develop what he describes as a "drug to help patients handle respiratory viruses." He explains that work on the drug lon...

SYGGF - Synairgen CEO lays out plans for 2023 and beyond

(NewsDirect) Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talks to Proactive following the release of full year results for calendar year 2022 - a year he says was "quite challenging at times." Marsden discusses the UK-based respiratory company's clinical development...

SYGGF - Synairgen plc 2021 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Synairgen plc in conjunction with their 2021 Q2 earnings call. For further details see: Synairgen plc 2021 Q2 - Results - Earnings Call Presentation

SYGGF - Title: Synairgen plc (SYGGF) CEO Richard Marsden on Q2 2021 Results - Earnings Call Transcript

Synairgen plc (SYGGF) Q2 2021 Earnings Conference Call September 30, 2021, 08:00 AM ET Company Participants Richard Marsden - CEO Conference Call Participants Presentation Operator 00:03 Good day, ladies and gentlemen, and welcome to the virtual briefing of Synairgen’s Unaudited Half-Y...

SYGGF - Synairgen plc reports FY results

Synairgen plc (SYGGF): FY GAAP EPS of -9.46p.Cash balances of £75.0MPress Release For further details see: Synairgen plc reports FY results

SYGGF - Synairgen's inhaled interferon beta treatment included in US NIH ACTIV-2 trial for COVID-19

UK-based nano cap Synairgen (SYGGF) announces that its inhaled interferon beta treatment has been included in the US NIH ACTIV-2 trial in COVID-19 outpatients.ACTIV partnership is funded by "Operation Warp Speed", led by the US Government’s Department of Health and Human Services and d...

SYGGF - FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

Palm Beach, FL – January 21, 2021 – Most of the news on advances for Covid-19 tend to focus on vaccines, however treatments are just as important. While vaccines can stop people from contracting Covid and becoming seriously ill, treatments will still be needed for those who al...

SYGGF - Synairgen plc reports 1H results

Synairgen plc (SYGGF): 1H GAAP EPS of -£3.11p.Cash and cash equivalentsof £10.88MR&D expenditure was £4.47M vs. £1.69M last year.In March 2020, Synairgen raised £14.0M (before expenses) in an equity issue to fund its initial COVID-19 related activities and st...

SYGGF - Acacia Research: Starboard Facilitates The Generation Of Absolute Return

Nearly a year ago, Acacia Research expanded its business strategy to generate absolute return. Starboard Value partnered with it to generate leads and provide financial backing. In June, Acacia entered into a purchase agreement with Link Fund Solutions to acquire public and private li...

Next 10